Indeed, prior studies have demonstrated that IDC + DCIS tumors are associated with favorable clinical characteristics such as smaller tumor size, lower tumor grade, lower Ki-67 staining, greater ER-positivity, and reduced risk of local recurrence when compared to IDC alone5–9. Here, ESR1 is linked to ductal breast carcinoma in situ.